Other targetable genomic alterations in NSCLC, including RET and ROS1 rearrangements and ERBB2, MET exon 14 skipping and PIK3CA mutations, are present only in a small percentage of NSCLC patients (~ 1–2% [49], ~ 2% [50], 2–4% [51–53], 3–4% [54–57] and 2–5% [26, 58, 59], respectively). Here, MET is linked to non-small cell lung carcinoma.